



ASX ANNOUNCEMENT

30 May 2024

## 2024 Annual Meeting of Stockholders Presentation of President & CEO

**Sunnyvale, California; 30 May 2024:** EBR Systems, Inc. (ASX: “EBR”, “EBR Systems”, or the “Company”), is pleased to provide the presentation of the President & CEO to be delivered at the Company’s virtual 2024 Annual Meeting of Stockholders today, Thursday, 30 May 2024 at 9:00am Australian Eastern Standard Time (Wednesday, 29 May 2024 at 4:00pm U.S. Pacific Daylight Time).

To attend the Annual Meeting, enter [meetnow.global/MLRAAYK](https://meetnow.global/MLRAAYK) into a web browser on your computer or other device with web access:

- CHES Depositary Interest (CDI) holders will need to select “Guest” and enter their name and email address;
- Shareholders will need to select “Stockholder” and enter their Shareholder Control Number which will have been provided by Computershare Investor Services; and
- Proxyholders (including CDI holders who have appointed themselves as CHES Depositary Nominees Pty Ltd’s<sup>1</sup> (CDN’s) proxy) will need to select “Invitation” and enter a proxy number which will have been provided by Computershare Investor Services.

Further information in relation to the Annual Meeting is set out in the Notice of Annual Meeting of Stockholders released on 30 April 2024.

ENDS

*This announcement has been authorised for release by the EBR Systems Routine Notifications Committee, a committee established by the Board of Directors.*

**For more information, please contact:**

**Company**

Gary Doherty  
Chief Financial Officer  
P: +1 408 720 1906  
E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

**Investors**

Joel Seah  
Vesparum Capital  
P: +61 3 8582 4800  
E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)

**About EBR Systems (ASX: EBR)**

Silicon Valley-based EBR Systems (ASX: EBR) is dedicated to superior treatment of cardiac rhythm disease by providing more physiologically effective stimulation through wireless cardiac pacing. The patented proprietary Wireless Stimulation Endocardially (WiSE) technology was developed to eliminate the need for cardiac pacing leads, historically the major source of complications, effectiveness, and reliability issues in cardiac rhythm disease management. The initial product is designed to eliminate the need for coronary sinus leads to stimulate the left ventricle in heart failure patients requiring Cardiac

<sup>1</sup> CHES Depositary Nominees Pty Ltd is the holder of record for all shares beneficially owned by holders of CDIs.

Resynchronisation Therapy (CRT). Future products potentially address wireless endocardial stimulation for bradycardia and other non-cardiac indications.

### **EBR Systems' WiSE Technology**

EBR Systems' WiSE technology is the world's only wireless, endocardial (inside the heart) pacing system in clinical use for stimulating the heart's left ventricle. This has long been a goal of cardiac pacing companies since internal stimulation of the left ventricle is thought to be a potentially superior, more anatomically correct pacing location. WiSE technology enables cardiac pacing of the left ventricle with a novel cardiac implant that is roughly the size of a large grain of rice. The need for a pacing wire on the outside of the heart's left ventricle – and the attendant problems – are potentially eliminated. WiSE is an investigational device and is not currently available for sale in the US.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions, and expectations and on information currently available to management. Forward-looking statements involve known and unknown risks, uncertainties, contingencies, and other factors, many of which are beyond the Company's control, subject to change without notice and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. EBR does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. EBR may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

### **Foreign Ownership Restriction**

EBR's CHES Depositary Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of EBR's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

ersonal use only



AGM Presentation

MAY 2024

# Year in review

## July 2023

- EBR completed A\$30m placement and A\$2.7m SPP<sup>1</sup>
- Successfully drew down US\$20m from growth capital facility
- Engaged with investors on Australian roadshow

## September 2023

- Positive additional results from the SOLVE-CRT study presented at APHRS<sup>2</sup>
- Appointed Gary Doherty as Chief Financial Officer

## November 2023

- Confirmed submission of four (out of five) modules for FDA PMA<sup>3</sup>

## December 2023


- Engaged with investors on Australian roadshow

## March 2024

- EBR officially included in the S&P / ASX All Ordinaries Index

## April 2024

- Appointed Erik Strandberg as Chief Commercial Officer



# Pivotal SOLVE-CRT Study meets primary endpoints

Positive results confirm WiSE CRT System as a highly effective treatment option for patients with heart failure<sup>1</sup>

## Primary efficacy endpoint met

**-16.4%**  
*p = 0.003*

Decrease in left ventricular end systolic volume (vs. -9.3% target), showing improved heart function



### Success in high-risk patients

SOLVE-CRT patient pool consists of patients who have failed conventional CRT



### Other key data

All data analysed to date shows consistent, positive results in reversing heart failure symptoms and physiology

## Primary safety endpoint met

**80.9%**  
*p < 0.001*

Patients free from type I complications (vs. 70% target)



### Safety profile comparable to SoC<sup>2</sup>

Other studies using SoC treatment for CRT upgrades have shown 81.3% freedom from device & procedure related complications<sup>3</sup>



### Other key data

Observed complication rates were higher in early phases and decreased with experience

# Commercialisation pathway

Positive pivotal trial results support EBR's regulatory approval process and underpin a clear pathway to commercialisation


1

Confidence in FDA approval process underpinned by positive pivotal trial results and a track record of successful engagement with the FDA resulting in:

- Award of Breakthrough Device Designation
- Approval of pivotal study re-design
- Approval of leadless pacemakers as a co-implant in pivotal study

2

- EBR has submitted four out of five required modules for the PMA submission
- The final module is related to biocompatibility & device verification testing which is currently underway



# Investment highlights

EBR is focused on executing its clear and targeted commercialisation strategy to deliver shareholder value

## High value market opportunity



### Unique solution

No competition - the WiSE CRT system is complementary to other leadless devices



### Large markets

Targeting initial addressable market of US\$2.6bn




### Positive results

Safety and efficacy endpoints met for SOLVE-CRT trial and Breakthrough Device Designation granted



### Focused strategy

Clear pathway to achieve FDA approval and progress commercialisation activities to achieve first sales



### Strong team

Experienced management team with significant clinical development and commercial expertise

# Disclaimer

The material contained in this document is a presentation of general information about the activities of EBR Systems, Inc. (ASX:EBR) (ARBN 654 147 127) and its subsidiaries (“EBR”) current as at the date of this presentation. It should be read in conjunction with EBR’s periodic and continuous disclosure announcements filed with the Australian Securities Exchange, available at [www.asx.com.au](http://www.asx.com.au).

The information in this presentation is provided in a summary form, does not purport to be complete and should not be relied upon as advice for investment purposes. This presentation is for information purposes only and is not financial product advice or a recommendation to acquire EBR securities. This presentation does not take into account the investment objectives, financial position or needs of any particular investor. Independent advice should be sought before making any investment decision.

The information in this presentation has been prepared by EBR in good faith and with due care, but the EBR does not make any representation or warranty, express or implied, as to the fairness, accuracy, correctness or completeness of the information, opinions or conclusions contained in this presentation. The information in this presentation is subject to change without notice and unless required by law, EBR assumes no obligation to update this presentation or its contents for any matter arising or coming to EBR’s notice after the date of this presentation.

Certain statements in this presentation may constitute forward-looking statements or statements about future matters that are based on management’s current expectations and beliefs. Such statements are typically identified by words such as ‘may’, ‘could’, ‘believes’, ‘estimates’, ‘expects’, ‘anticipates’, ‘intends’ and other similar words. These statements are subject to risks and uncertainties that are difficult to predict and are based on assumptions as to future events that may not prove accurate. Actual results may differ materially from what is expressed in this presentation.

To the maximum extent permitted by law, no responsibility for any loss arising in any way (including by way of negligence) from anyone acting or refraining to act as a result of this presentation or its contents is accepted by EBR or any of its officers, employees or agents.

The distribution of this presentation outside of Australia may be restricted by law and any such restrictions should be observed. This presentation does not constitute an offer to sell, or a solicitation of an offer to buy, securities in Australia, the United States or any other jurisdiction.

Investors should note that this presentation may contain unaudited financial information that has been prepared by EBR’s management. EBR’s results are reported under US GAAP. Certain financial data in this presentation is “non-IFRS financial information” under Regulatory Guide 230 (Disclosing non-IFRS financial information) published by ASIC. All values are stated in U.S. dollars unless otherwise stated.

EBR’s CHES Depositary Interests (“CDIs”) are traded on ASX in reliance on the safe harbour provisions of Regulation S under the US Securities Act of 1933, as amended, and in accordance with the procedures established pursuant to the provisions of a no-action letter dated 7 January 2000 given to ASX by the staff at the US Securities and Exchange Commission. The relief was given subject to certain procedures and conditions described in the no-action letter. One of the conditions is that the issuer provides notification of the Regulation S status of its securities in communications such as this presentation.



ersonal use only



## Contact us

### Company

John McCutcheon

President & CEO

P: +1 408 720 1906

E: [info@ebrsystemsinc.com](mailto:info@ebrsystemsinc.com)

### Investors

Joel Seah

Vesparum Capital

P: +61 3 8582 4800

E: [EBRSystems@vesparum.com](mailto:EBRSystems@vesparum.com)